Proactive Investors - Run By Investors For Investors
Why invest in ZLD?
Zelda Therapeutics Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Zelda Therapeutics begins observational trial for medicinal cannabis treatment of autism

Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
Laboratory testing
INVESTMENT OVERVIEW: ZLD The Big Picture
Zelda is developing medicinal cannabis therapies for autism, insomnia and cancer

Zelda Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) has started recruitment for an autism observational trial in the USA centred on medicinal cannabis treatment.

Fifteen patients have been formally enrolled and first results are expected in the first half of 2019.

The trial, which is seeking to better understand the efficacy of medicinal cannabis treatment in existing patients, is being carried out at Children’s Hospital of Philadelphia (CHOP) in the USA.

“Diagnosis rates on the rise”

Zelda and CHOP will work closely with patient advocacy groups during the trial.

The company’s managing director Dr Richard Hopkins said, “We are excited to have this study underway and to be working alongside CHOP to conduct one of the first formal, robust studies of its type in the world.

“With studies showing that around one in 100 people have autism and with diagnosis rates on the rise, we’re focused on addressing a major unmet need for potential new therapies to help treat this condition.”

The study will utilise CHOP’s extensive research infrastructure and is designed to capture a number of key efficacy and safety measures, including clinical pharmacological data using a novel micro-sampling technique developed by CHOP.

Pediatric patients already being treated with medicinal cannabis formulations will be monitored.

Possible future clinical trial

It will lay the groundwork for a possible future clinical trial to generate high-quality, robust and acceptable data to validate the existing anecdotal data amongst patient populations.

The ultimate goal is to identify cannabinoid-based compounds that may demonstrate efficacy in the treatment of pediatric autism.

Developing cannabinoid-based formulations

Zelda is an Australian-based bio-pharmaceutical company focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company has a two-armed strategy comprising:

- A human clinical trial program focused on insomnia and autism with activities in Australia, Chile and the USA.

- A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

READ: Zelda Therapeutics doses first patient in insomnia clinical trial

The company recently dosed the first patient in its medical cannabis insomnia clinical trial with results expected in the first half of 2019.

A randomised, placebo-controlled, crossover study design will be used to treat 24 patients with Zelda’s medicinal cannabis formulation.

The study will collect and analyse data to determine the effect of the formulation on the time it takes to fall asleep, time spent awake and asleep during the night and quality of sleep.

READ: Zelda Therapeutics enters German medical cannabis market with partnership

Another recent development has been a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.

Under this arrangement, HAPA has first rights to distribute and/or manufacture Zelda’s clinically validated formulations into the rapidly growing German market.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.
A marijuana plant
Fri
The company is bullish with 10 US states and Canada having legalized recreational marijuana
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use